Conditions: Pulmonary Arterial Hypertension Pulmonary Hypertension
Keywords: endothelin receptor antagonist (ETRA) Sitaxsentan
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 131
Healthy volunteers: no

Brief summary:
As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled safety/efficacy database of the combination is limited.

Detailed description:

Arms:
arm 1: Monotherapy arm arm 2: Combination treatment

Interventions: intervention 1: Sitaxsentan intervention 2: Sitaxsentan and Sildenafil
Intervention descriptions: intervention 1: Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day intervention 2: Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day

Protocol document: